Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate
Centauri Therapeutics Limited (‘Centauri’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6 M from…